These findings suggest that targeted modulation of the Tim-3 and MHC-II pathway, potentially through Tim-3 agonists, may offer a novel therapeutic strategy for restoring immune tolerance in MS (67). The gene discussed is HAVCR2; the disease is myeloid sarcoma.